Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trump Praises Record Device Approvals, Pushes Congress To Pass 'Right-To-Try' Bills

Executive Summary

In his Jan. 30 State of the Union address, President Trump praised US FDA for its high approval rate of devices and drugs in 2017, and urged Congress to do more by approving 'right-to-try' legislation that he says would allow terminally ill patients to gain access to experimental devices and drugs.

You may also be interested in...

No-Device 'Right-To-Try' Bill Fails To Pass House Muster

"Right-to-try" legislation aimed at giving severely ill patients access to drug treatments not yet approved by US FDA failed to win support from the needed super-majority in a Tuesday night vote in the US House. Before the vote, the bill's scope was narrowed by removing medical device provisions, and making it applicable only to those facing death within a matter of months. A Senate version still in play retains the device language.

No New US FDA Effort To Turn 'Right-To-Try' Bills Into Law

President Trump's statement at a Feb. 1 Republican retreat that US FDA Commissioner Scott Gottlieb is "heading up" an effort to make "right-to-try" legislation that would permit easier access to unapproved devices and drugs is not a sign that FDA supports current bills in Congress on the topic, an FDA spokeswoman said.

US Congress Ends Shutdown, Clinches Two-Year Device-Tax Repeal

Congress reached agreement Jan. 22 to end the three-day US government shutdown in a continuing resolution bill that includes a two-year device-tax suspension.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts